Issue link: https://nebusinessmedia.uberflip.com/i/1437423
n e w h a v e n b i z . c o m | B o o k o f L i s t s 2 0 2 1 | n e w h a v e n B I Z 43 2 0 2 1 B o o k o f L i s t s - I N N O V A T I O N Largest Bioscience/Biotechnology Companies South Central Connecticut (Ranked by number of employees) Rank Company No. CT employees/ No. total employees Headquarters/ Focus Ownership/ Ticker Chief executive/ Year founded 1 Pfizer Inc. 1 Howe St. New Haven, CT 06511 (a) 203-401-0100; www.pfizer.com 2,700 (b) 78,500 New York, NY Pharmaceutical research, development and manufacturing Public NYSE: PFE Albert Bourla CEO 1849 2 Medtronic Inc. 60 Middletown Ave. North Haven, CT 06473 203-492-5000; www.medtronic.com 2,500 90,000 Dublin, Ireland Development, manufacturing and sales of surgical staplers Public NYSE: MDT Geoffrey S. Martha CEO 1949 3 Sema4 1 Commercial St. Branford, CT 06405 800-298-6470; sema4.com 634 1,148 Stamford Patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights Public NASDAQ: SMFR Eric Schadt Founder & CEO 2017 4 Alexion Pharmaceuticals Inc. (c) 100 College St. New Haven, CT 06510 475-230-2596; alexion.com 500 3,800 Cambridge, United Kingdom Severe and life-threatening rare disorders Public NASDAQ: AZN Marc Dunoyer CEO, Alexion and CFO, AstraZeneca 1992 5 PerkinElmer Inc. 710 Bridgeport Ave. Shelton, CT 06484 (d) 203-925-4600; www.perkinelmer.com 396 14,000 Waltham, MA Detection, imaging, informatics, software and services innovating for a healthier world Public NYSE: PKI Prahlad Singh CEO 1937 6 CooperSurgical Inc. (e) 75 Corporate Drive Trumbull, CT 06611 203-601-5200; www.coopersurgical.com 250 (f) 12,000 (g) Trumbull Development and commercialization of medical devices and diagnostics for women's health Public NYSE: COO (h) Holly Sheffield President 1990 7 Arvinas Inc. 5 Science Park, 395 Winchester Ave. New Haven, CT 06511 203-535-1456; www.arvinas.com 216 216 New Haven Development of therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare disease Public NASDAQ: ARVN John Houston President & CEO 2013 8 Biohaven Pharmaceutical Holding Co. 215 Church St. New Haven, CT 06510 203-404-0410; biohavenpharma.com 100 900 New Haven Neuroscience Public NYSE: BHVN Vlad Coric CEO 2013 8 Protein Sciences, a division of Sanofi 1000 Research Parkway Meriden, CT 06450 203-427-2403; www.sanofi.com 100 100,000 (i) Paris, France Vaccine development and protein production Public NASDAQ: SNY (j) Paul Hudson CEO, Sanofi 1994 10 Quantum-Si Inc. 520 Old Whitfield St. Guilford, CT 06437 203-458-7100; www.quantum-si.com 80 121 Guilford Life sciences; protein sequencing Public NASDAQ: QSI John Stark CEO 2013 11 BioXcel Therapeutics 555 Long Wharf Drive New Haven, CT 06511 475-238-6837; bioxceltherapeutics.com 50 83 New Haven Biopharmaceutical firm using artificial intelligence to advance development of medicines for neuroscience, immuno-oncology and other diseases Public NASDAQ: BTAI Vimal D. Mehta Founder & CEO 2017 12 Precipio Inc. 4 Science Park, 3rd Floor New Haven, CT 06511 203-787-7888; www.precipiodx.com 40 60 New Haven Genetic testing Public NASDAQ: PRPO Ilan Danieli CEO 2017 (k) 13 Tangen Biosciences Inc. 20 Commercial St. Branford, CT 06405 203-433-4045; tangenbiosciences.com 33 33 Branford Molecular diagnostics Private Richard C. Birkmeyer President & CEO 2013 14 Rallybio Corporation 234 Church St., Suite 1020 New Haven, CT 06510 203-859-3820; rallybio.com 31 31 New Haven Identifying and accelerating the development of transformative therapies for patients with severe and rare disorders Public (l) NASDAQ: RLYB Martin Mackay Co-founder & CEO 2018 15 Celldex Therapeutics Inc. 300 George St., Suite 530 New Haven, CT 06511 203-483-3500; celldex.com 25 125 (m) Hampton, NJ Immunotherapy, therapeutic antibodies, antibody drug conjugates, immune system modulators Public NASDAQ:CLDX Anthony Marucci President & CEO 2005 16 Cybrexa Therapeutics 5 Science Park, 395 Winchester Ave. New Haven, CT 06511 860-717-2731; cybrexa.com 23 23 New Haven Development of therapies using Alphalex platform to deliver anti- cancer agents directly into tumor cells Private Per Hellsund President & CEO 2017 17 Azitra Inc. 21 Business Park Drive Branford, CT 06405 203-646-6446; azitrainc.com 20 26 Branford Clinical-stage medical dermatology company addressing serious skin conditions by harnessing the microbiome Private Francisco Salva CEO 2014 17 Halda Therapeutics 115 Munson St. New Haven, CT 06511 475-210-0212 20 20 New Haven Platform technologies to target cancer cells Private Craig Crews Founder 2019 17 NanoViricides Inc. 1 Controls Drive Shelton, CT 06484 203-937-6137; nanoviricides.com 20 25 Shelton Developer of nanomedicine drugs against viruses Public NYSE: NNVC Anil R. Diwan President & chairman 2005 20 Wellinks (n) 85 Willow St. New Haven, CT 06511 844-359-7632; www.wellinks.com 17 19 New Haven Developer of wearable health technology, software and hardware Private Alex Waldron CEO 2017 21 Trevi Therapeutics 195 Church St. New Haven, CT 06510 203-304-2499; www.trevitherapeutics.com 16 25 New Haven Developer of nalbuphine ER to treat serious neurologically mediated conditions by targeting the central and peripheral nervous systems Public NASDAQ: TRVI Jennifer L. Good Co-founder, president & CEO 2011 22 New England Discovery Partners (o) 23 Business Park Drive Branford, CT 06405 203-208-2523; nedp.com 15 15 Branford Contract research in synthetic and medicinal chemistry; drug discovery services to academic, pharmaceutical and biotechnology companies Private Michael Van Zandt President & CEO 2012 23 Artizan Biosciences 150 Munson St., Suite 210 New Haven, CT 06511 www.artizanbiosciences.com 12 14 New Haven Research and development of treatments for inflammatory diseases through innovation of microbiota-targeted therapies Private Bridget Martell James Rosen co-CEOs 2016 24 Fitscript LLC 5 Science Park New Haven, CT 06511 203-677-0969; glucosezone.com (p) 9 12 New Haven Health and fitness technology Private Charles O'Connell CEO 2012 Sources: Each company via survey, website and/or press releases, annual 10-K reports to SEC and Labor Market Information database, Conn. Dept of Labor. Notes: N/A = not available or not applicable. In August 2020, Clinton-based Ce3 merged into North Carolina-based Catalyst Clinical Research; local employee count could not be confirmed. (a) Address for Clinical Research Unit with a second Conn. site in Groton. (b) Approximate number of statewide employees. Including contractors assigned to Conn. sites, employee count is 5,281. (c) A subsidiary of AstraZeneca. (d) With an additional R&D operation in Branford. (e) A wholly owned subsidiary of The Cooper Companies. (f) Number of employees is 250-499 according to CT Department of Labor, Labor Market Information. (g) As of October 31, 2020 as reported to SEC, form 10-K. (h) For parent company, The Cooper Companies. (i) Greater than 100,000 worldwide, Sanofi. (j) For parent company Sanofi S.A. based in Paris, France. (k) Year founded as a result of the merger with Transgenomics Inc. (l) On Aug. 2, 2021, announced closing of initial public offering of public shares with the U.S. Securities & Exchange Commission (m) As of Dec. 2020, per SEC 10-K filing FY ending Dec. 31, 2020. (n) Wellinks was acquired by Convexity Scientific Inc. on January 2020. The company rebranded as Wellinks. (o) Part of N.J.-based Genesis Drug Discovery & Development (GD3), a member of Genesis Biotechnology Group. (p) Website for GlucoseZone digital exercise program created by Fitscript LLC. —Compiled by Heide Martin. Largest Bioscience/Biotechnology Companies, South Central Connecticut Ranked by number of Connecticut employees